David de Gruijl

David de Gruijl is the Co-founder of Anto, a biotechnology and healthtech startup focused on advancing novel therapies and commercializing early-stage medical technologies. Prior to launching his current venture, he established a background in pharmaceutical research and clinical gastroenterology across several prominent international research institutions. His professional industry experience includes specialized research and drug development roles at Janssen Pharmaceuticals, where he worked directly on translational medicine initiatives. Additionally, de Gruijl held academic research positions at ETH Zurich and within the Gastroenterology Department at Brigham and Women's Hospital, a primary teaching affiliate of Harvard Medical School. His career trajectory bridges the operational gap between academic scientific research and commercial biotechnology ventures. He currently focuses on leveraging his clinical expertise to build new healthcare solutions and drive early-stage drug discovery in the gastroenterology sector.